Literature DB >> 26717019

Determination and quantitation of sildenafil and its major metabolite in the breast milk of a lactating woman.

Uwe Wollein1, Bernd Schech1, Jochen Hardt2, Nicholas Schramek3.   

Abstract

A heavily pregnant woman was treated with Revatio(®) (Sildenafil) against idiopathic pulmonary arterial hypertension, prior to and after her accouchement. To investigate the transfer of sildenafil into breast milk and its metabolism shortly before breastfeeding to the neonatal, a new analytical method was developed and validated, using liquid chromatography tandem mass spectrometry. Additionally, while using linear ion trap scan mode experiments, further metabolites could be identified. Sample preparation was carried out, using solid-phase extraction. For quantification of sildenafil and its major metabolite N-desmethylsildenafil, sildenafil-d8 was used as an internal standard. Within a time frame of 17h covering two Revatio(®) intakes and three breast milk samplings, a concentration range from 1.64 to 4.49ng/ml (sildenafil) and from 1.18 to 1.82ng/ml (N-desmethylsildenafil) could be observed. The current method proved to be accurate and precise in a very low concentration range and establishes the first reported determination of sildenafil and N-desmethylsildenafil in human breast milk.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Human breast milk; Metabolite screening; Pulmonary arterial hypertension; SPE sample work up; Sildenafil

Mesh:

Substances:

Year:  2015        PMID: 26717019     DOI: 10.1016/j.jpba.2015.12.006

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  1 in total

1.  Case Report: Bosentan and Sildenafil Exposure in Human Milk - A Contribution From the ConcePTION Project.

Authors:  Nina Nauwelaerts; Michael Ceulemans; Neel Deferm; An Eerdekens; Bart Lammens; Yeghig Armoudjian; Kristel Van Calsteren; Karel Allegaert; Loes de Vries; Pieter Annaert; Anne Smits
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.